NASDAQ:VIR Vir Biotechnology (VIR) Stock Forecast, Price & News $26.05 +0.28 (+1.09%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$25.66▼$26.2650-Day Range$22.26▼$26.7352-Week Range$18.05▼$31.78Volume618,152 shsAverage Volume854,783 shsMarket Capitalization$3.49 billionP/E RatioN/ADividend YieldN/APrice Target$49.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Vir Biotechnology MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside91.0% Upside$49.75 Price TargetShort InterestBearish6.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.08Based on 14 Articles This WeekInsider TradingSelling Shares$22.10 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.80) to ($4.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.81 out of 5 starsMedical Sector793rd out of 1,012 stocksBiological Products, Except Diagnostic Industry129th out of 169 stocks 3.4 Analyst's Opinion Consensus RatingVir Biotechnology has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $49.75, Vir Biotechnology has a forecasted upside of 91.0% from its current price of $26.05.Amount of Analyst CoverageVir Biotechnology has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.00% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 7.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIR. Previous Next 1.7 News and Social Media Coverage News SentimentVir Biotechnology has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Vir Biotechnology this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,101,441.00 in company stock.Percentage Held by Insiders18.10% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.97% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vir Biotechnology are expected to decrease in the coming year, from ($3.80) to ($4.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -23.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -23.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vir Biotechnology (NASDAQ:VIR) StockVir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.Read More Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Stock News HeadlinesMay 28, 2023 | americanbankingnews.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells $2,729,641.60 in StockMay 27, 2023 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Shares Gap Down Following Insider SellingMay 28, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 26, 2023 | fool.comVir Biotechnology (NASDAQ: VIR)May 26, 2023 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells $2,326,102.38 in StockMay 26, 2023 | americanbankingnews.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells $2,363,565.12 in StockMay 25, 2023 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by AnalystsMay 24, 2023 | americanbankingnews.comContrasting Vir Biotechnology (NASDAQ:VIR) & BioCardia (NASDAQ:BCDA)May 28, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 18, 2023 | seekingalpha.comVir Biotechnology (VIR) Investor Presentation - SlideshowMay 17, 2023 | finance.yahoo.comVir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of StockholdersMay 15, 2023 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 50% of the companyMay 15, 2023 | finance.yahoo.comVir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business OfficerMay 13, 2023 | americanbankingnews.comHC Wainwright Weighs in on Vir Biotechnology, Inc.'s Q3 2023 Earnings (NASDAQ:VIR)May 11, 2023 | finance.yahoo.comVir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTIMay 9, 2023 | bizjournals.comRetired Vir CEO George Scangos lands on two boards with links to old companyMay 9, 2023 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) to Post Q4 2023 Earnings of $1.04 Per Share, SVB Leerink ForecastsMay 8, 2023 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells $2,134,523.74 in StockMay 8, 2023 | americanbankingnews.comSVB Securities Lowers Vir Biotechnology (NASDAQ:VIR) Price Target to $42.00May 7, 2023 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Shares Gap Down Following Weak EarningsMay 6, 2023 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 3,075 SharesMay 4, 2023 | finance.yahoo.comVir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue EstimatesMay 4, 2023 | finance.yahoo.comVir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 4, 2023 | benzinga.comVir Biotechnology 10% Owner Sold $77K In Company StockMay 3, 2023 | finance.yahoo.comVir Biotechnology to Participate in the BofA Securities 2023 Health Care ConferenceMay 2, 2023 | finance.yahoo.comVir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV PreventionApril 29, 2023 | americanbankingnews.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells $1,678,685.96 in StockSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Company Calendar Last Earnings5/04/2023Today5/28/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VIR CUSIPN/A CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees444Year FoundedN/APrice Target and Rating Average Stock Price Forecast$49.75 High Stock Price Forecast$100.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+91.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$515.84 million Net MarginsN/A Pretax Margin-69.64% Return on Equity-7.05% Return on Assets-5.33% Debt Debt-to-Equity RatioN/A Current Ratio4.86 Quick Ratio4.86 Sales & Book Value Annual Sales$1.62 billion Price / Sales2.16 Cash Flow$3.86 per share Price / Cash Flow6.75 Book Value$14.71 per share Price / Book1.77Miscellaneous Outstanding Shares133,980,000Free Float109,727,000Market Cap$3.49 billion OptionableOptionable Beta0.26 Key ExecutivesDr. George A. Scangos Ph.D. (Age 75)Pres, CEO & Director Comp: $1.07MMr. Howard Horn (Age 45)Exec. VP, CFO & Sec. Comp: $732.41kDr. Ann M. Hanly Ph.D. (Age 53)Exec. VP & Chief Technology Officer Comp: $922.22kDr. Phillip Pang M.D. (Age 48)Ph.D., Exec. VP, Chief Medical Officer & Interim Head of Research Comp: $780.46kDr. Klaus Frueh Ph.D. (Age 63)Co-Founder & Scientific Advisor Dr. Lawrence Corey M.D.Co-Founder & Scientific AdvisorDr. Louis J. Picker M.D.Co-Founder & Scientific AdvisorMs. Johanna Friedl-Naderer (Age 55)Exec. VP & COO Mr. Steven J. Rice (Age 63)Exec. VP & Chief Admin. Officer Ms. Heather Rowe ArmstrongVP of Investor RelationsMore ExecutivesKey CompetitorsAbcamNASDAQ:ABCMGinkgo BioworksNYSE:DNAKrystal BiotechNASDAQ:KRYSImmunovantNASDAQ:IMVTRevolution MedicinesNASDAQ:RVMDView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 3,841 shares on 5/26/2023Ownership: 0.015%Endurance (Cayman) Ltd SvfSold 104,384 sharesTotal: $2.73 M ($26.15/share)Royce & Associates LPSold 5,596 shares on 5/23/2023Ownership: 0.038%Toroso Investments LLCBought 20,015 shares on 5/23/2023Ownership: 0.015%Capital Impact Advisors LLCSold 5,963 shares on 5/23/2023Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions VIR Stock - Frequently Asked Questions Should I buy or sell Vir Biotechnology stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VIR shares. View VIR analyst ratings or view top-rated stocks. What is Vir Biotechnology's stock price forecast for 2023? 6 Wall Street research analysts have issued 1-year target prices for Vir Biotechnology's shares. Their VIR share price forecasts range from $27.00 to $100.00. On average, they predict the company's share price to reach $49.75 in the next twelve months. This suggests a possible upside of 91.0% from the stock's current price. View analysts price targets for VIR or view top-rated stocks among Wall Street analysts. How have VIR shares performed in 2023? Vir Biotechnology's stock was trading at $25.31 at the beginning of the year. Since then, VIR shares have increased by 2.9% and is now trading at $26.05. View the best growth stocks for 2023 here. When is Vir Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our VIR earnings forecast. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) released its quarterly earnings data on Thursday, May, 4th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by $0.20. The business earned $63 million during the quarter, compared to the consensus estimate of $50.10 million. The company's revenue was down 94.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.93 EPS. What ETFs hold Vir Biotechnology's stock? ETFs with the largest weight of Vir Biotechnology (NASDAQ:VIR) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Hartford Multifactor Small Cap ETF (ROSC), SPDR S&P Biotech ETF (XBI) and ETC 6 Meridian Small Cap Equity ETF (SIXS). What is George Scangos' approval rating as Vir Biotechnology's CEO? 7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees. When did Vir Biotechnology IPO? (VIR) raised $149 million in an initial public offering on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO. What is Vir Biotechnology's stock symbol? Vir Biotechnology trades on the NASDAQ under the ticker symbol "VIR." Who are Vir Biotechnology's major shareholders? Vir Biotechnology's stock is owned by many different retail and institutional investors. Top institutional shareholders include SB Investment Advisers UK Ltd. (13.67%), BlackRock Inc. (10.42%), Temasek Holdings Private Ltd (4.34%), State Street Corp (4.02%), Baillie Gifford & Co. (2.98%) and Geode Capital Management LLC (1.14%). Insiders that own company stock include Ann M Hanly, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Jay Parrish, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vir Biotechnology's stock price today? One share of VIR stock can currently be purchased for approximately $26.05. How much money does Vir Biotechnology make? Vir Biotechnology (NASDAQ:VIR) has a market capitalization of $3.49 billion and generates $1.62 billion in revenue each year. The company earns $515.84 million in net income (profit) each year or ($1.10) on an earnings per share basis. How many employees does Vir Biotechnology have? The company employs 444 workers across the globe. How can I contact Vir Biotechnology? Vir Biotechnology's mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The official website for the company is www.vir.bio. The company can be reached via phone at 415-906-4324 or via email at ir@vir.bio. This page (NASDAQ:VIR) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.